Persistent extended-spectrum β-lactamase urinary tract infection

Emerging Infectious Diseases

Volumn 15, Issue 11, 2009, Pages 1862-1864

  DeBusscher, Joan ^a   Zhang, Lixin ^a   Buxton, Miatta ^a   Foxman, Betsy ^a   Barbosa Cesnik, Cibele ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; NITROFURANTOIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADULT; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; CASE REPORT; CLINICAL TRIAL; COLLEGE STUDENT; COMMUNITY; CRANBERRY JUICE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; GENOTYPE; HEALTH SERVICE; HUMAN; LETTER; MEDICAL RECORD REVIEW; PHYSICIAN; POLYMERASE CHAIN REACTION; PYURIA; RECTUM; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; VAGINA;

BETA-LACTAMASES; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; UNITED STATES; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 70350449622     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1511.081501     Document Type: Letter

References (8)

1. Lewis JS II, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother. 2007;51:4015-4021 DOI: 10.1128/AAC.00576-07 (Pubitemid 350057800)
2. Doi Y, Adams J, O'Keefe A, Quereshi Z, Ewan L, Paterson DL. Community-acquired extended-spectrum beta-lactamase producers, United States. Emerg Infect Dis. 2007;13:1121-1123
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement M100-S18. 2008;28:162-3, 174-175
4. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S-13S. DOI: 10.1016/S0002-9343-(02)01054-9 (Pubitemid 34756640)
5. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empiric therapy. Clin Infect Dis. 2004;39:75-80. DOI: 10.1086/422145 (Pubitemid 38879552)
6. Moland ES, Kim S-Y, Hong SG, Thomson KS. Newer β-lactamases: clinical and laboratory implications, Part II. Clin Microbiol Newsl. 2008;30:79-85. DOI: 10.1016/j.clinmicnews.2008.05.001
7. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended- spectrum β-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897-1902 DOI: 10.1001/ archinte.168.17.1897
8. Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, et al. Screening for extended- spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis. 2007;45:846-852 DOI: 10.1086/521260